Orgenesis Inc. (NASDAQ:ORGS – Get Free Report)’s stock price dropped 45.4% on Friday . The company traded as low as $0.30 and last traded at $0.30. Approximately 725 shares changed hands during mid-day trading, an increase of 36% from the average daily volume of 533 shares. The stock had previously closed at $0.5495.
Orgenesis Stock Down 45.4%
The company’s 50-day moving average is $0.32 and its two-hundred day moving average is $0.39. The company has a market cap of $1.55 million, a P/E ratio of -0.04 and a beta of 3.42.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Further Reading
- Five stocks we like better than Orgenesis
- The gold chart Wall Street is terrified of…
- This makes me furious
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
